Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BIIB logo BIIB
Upturn stock ratingUpturn stock rating
BIIB logo

Biogen Inc (BIIB)

Upturn stock ratingUpturn stock rating
$134.94
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: BIIB (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

37 Analysts rated it

Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.

1 Year Target Price $168.08

1 Year Target Price $168.08

Analysts Price Target For last 52 week
$168.08 Target price
52w Low $110.04
Current$134.94
52w High $207.59

Analysis of Past Performance

Type Stock
Historic Profit -9.31%
Avg. Invested days 40
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 19.78B USD
Price to earnings Ratio 12.91
1Y Target Price 168.08
Price to earnings Ratio 12.91
1Y Target Price 168.08
Volume (30-day avg) 37
Beta 0.13
52 Weeks Range 110.04 - 207.59
Updated Date 08/14/2025
52 Weeks Range 110.04 - 207.59
Updated Date 08/14/2025
Dividends yield (FY) -
Basic EPS (TTM) 10.45

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-30
When Before Market
Estimate 4.07
Actual 5.47

Profitability

Profit Margin 15.31%
Operating Margin (TTM) 34.61%

Management Effectiveness

Return on Assets (TTM) 5.62%
Return on Equity (TTM) 9.13%

Valuation

Trailing PE 12.91
Forward PE 9.44
Enterprise Value 23656627503
Price to Sales(TTM) 1.98
Enterprise Value 23656627503
Price to Sales(TTM) 1.98
Enterprise Value to Revenue 2.37
Enterprise Value to EBITDA 8.47
Shares Outstanding 146615008
Shares Floating 146220205
Shares Outstanding 146615008
Shares Floating 146220205
Percent Insiders 0.15
Percent Institutions 90.9

ai summary icon Upturn AI SWOT

Biogen Inc

stock logo

Company Overview

overview logo History and Background

Biogen Inc. was founded in 1978 in Geneva, Switzerland, by several prominent biologists, including Walter Gilbert and Phillip Sharp. It pioneered recombinant DNA technology and initially focused on interferon research. The company relocated to Cambridge, Massachusetts, and evolved into a leader in neuroscience, developing treatments for multiple sclerosis and other neurological diseases.

business area logo Core Business Areas

  • Multiple Sclerosis (MS): Biogen's historical and still significant revenue driver. Includes drugs like Tysabri, Tecfidera and Vumerity.
  • Spinal Muscular Atrophy (SMA): Led by Spinraza, a groundbreaking treatment for SMA.
  • Alzheimer's Disease: Aduhelm and Leqembi (partnered with Eisai) represent Biogen's foray into Alzheimer's treatment.
  • Biosimilars: Biogen develops and markets biosimilars of other companies' products.

leadership logo Leadership and Structure

As of late 2024, Christopher Viehbacher serves as the President and Chief Executive Officer. Biogen operates with a functional organizational structure with key divisions focused on research, development, commercial operations, and manufacturing.

Top Products and Market Share

overview logo Key Offerings

  • Spinraza: Treatment for Spinal Muscular Atrophy (SMA). Competitors include Novartis (Zolgensma) and Roche (Evrysdi). Spinraza held a significant share of the SMA market, but faces increasing competition and revenue has decreased since 2021. Revenue 2023: ~$1.5 Billion.
  • Tysabri: Treatment for Multiple Sclerosis. Competitors include Novartis (Gilenya, Kesimpta), Roche (Ocrevus), Sanofi (Aubagio). Tysabri's market share has been declining due to newer, more effective oral therapies. Revenue 2023: ~$1.8 Billion.
  • Tecfidera: Oral treatment for Multiple Sclerosis (MS). Tecfidera's revenue has declined sharply due to generic competition. Once a blockbuster drug, now facing severe erosion.
  • Vumerity: Oral treatment for MS, a successor to Tecfidera with an improved profile. Revenue 2023: ~$1.1 Billion.
  • Leqembi: Alzheimer's disease treatment developed with Eisai. Revenue 2023: ~$19 Million (early stages of commercialization).

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and long product development cycles. It's a highly competitive market, with constant innovation and patent battles. Increasing focus on rare diseases and gene therapies. Pricing and reimbursement pressures are significant challenges.

Positioning

Biogen is a leading biotechnology company specializing in neurological and neurodegenerative diseases. It has a strong history of innovation in multiple sclerosis and SMA, but is facing challenges due to competition, patent expirations, and launch of new therapies.

Total Addressable Market (TAM)

The global neurology market is projected to reach hundreds of billions of dollars. Biogen is strategically positioned in several high-growth segments, including MS, SMA, and Alzheimer's. Alzheimer's TAM is estimated to be $100 billion or more. Successful commercialization of Leqembi is crucial for Biogen to significantly expand its market share.

Upturn SWOT Analysis

Strengths

  • Strong expertise in neuroscience
  • Established commercial infrastructure
  • Diversified product portfolio (though concentrated)
  • Partnerships with leading research institutions and other companies
  • Significant experience in biologics development and manufacturing

Weaknesses

  • Dependence on a few key products
  • Patent expirations on key drugs
  • High R&D spending
  • Regulatory challenges and uncertainty
  • Past controversies and setbacks with certain drug launches (Aduhelm)
  • Increasing generic competition

Opportunities

  • Expansion into new therapeutic areas (e.g., immunology, gene therapy)
  • Growth in emerging markets
  • Strategic acquisitions and partnerships
  • Development of next-generation therapies
  • Successful commercialization of Leqembi

Threats

  • Competition from other biotechnology and pharmaceutical companies
  • Pricing pressures from payers and governments
  • Unsuccessful clinical trials
  • Regulatory hurdles
  • Generic erosion of existing products
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • RHHBY
  • SNY

Competitive Landscape

Biogen faces intense competition from large pharmaceutical companies and specialized biotechnology firms. It needs to differentiate itself through innovation and strategic partnerships. Leqembi's success is critical to its competitive positioning in the Alzheimer's market.

Major Acquisitions

Reata Pharmaceuticals

  • Year: 2023
  • Acquisition Price (USD millions): 7300
  • Strategic Rationale: Expansion into rare neurological diseases, specifically Friedreich's ataxia, with the acquisition of Skyclarys.

Growth Trajectory and Initiatives

Historical Growth: Biogen experienced significant growth in the past, driven by its MS franchise and Spinraza. However, growth has slowed in recent years due to competition and patent expirations.

Future Projections: Analysts project modest revenue growth for Biogen in the coming years, dependent on the successful launch of Leqembi and other pipeline products. Cost-cutting measures are expected to improve profitability. Analyst estimates vary widely depending on the success of the Alzheimer's program.

Recent Initiatives: Focus on cost optimization and operational efficiencies, including layoffs. Launching Leqembi with Eisai. Pipeline development in new therapeutic areas. Exploring strategic acquisitions and partnerships.

Summary

Biogen is a biotechnology company facing headwinds from generic competition and past missteps, but the acquisition of Reata and focus on new products like Leqembi can help them continue to grow. Its established infrastructure and neuroscience expertise are strengths, but dependence on a few key products and intense competition are ongoing concerns. The company needs to effectively execute its Leqembi launch and invest in innovative therapies to secure its future. With Alzheimeru2019s being an industry problem, Biogen has taken the right steps to be a player in the future of treatment.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Biogen Inc. Annual Reports
  • SEC Filings
  • Analyst Reports
  • Market Research Reports
  • Company Investor Presentations

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Market data and analyst estimates are subject to change. Past performance is not indicative of future results.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biogen Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 1991-09-16
President, CEO & Director Mr. Christopher A. Viehbacher
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 7605
Full time employees 7605

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.